Public health interventions to protect against falsified medicines: A systematic review of international, national and local policies

Health Policy and Planning

Volumn 31, Issue 10, 2016, Pages 1448-1466

  Hamilton, William L ^a,b   Doyle, Cormac ^a   Halliwell Ewen, Mycroft ^a   Lambert, Gabriel ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

antibiotic; antimalarial; counterfeit; drugs; Falsified; medicine; medicine safety; pharmaceutical; pharmacovigilance; poor quality; substandard

Indexed keywords

COUNTERFEIT DRUG;

DEVELOPING COUNTRY; DRUG LEGISLATION; GLOBAL HEALTH; GOVERNMENT REGULATION; HEALTH CARE POLICY; HUMAN; LEGISLATION AND JURISPRUDENCE; PUBLIC HEALTH; QUALITY CONTROL; STANDARDS;

COUNTERFEIT DRUGS; DEVELOPING COUNTRIES; GLOBAL HEALTH; GOVERNMENT REGULATION; HEALTH POLICY; HUMANS; LEGISLATION, DRUG; PUBLIC HEALTH; QUALITY CONTROL;

EID: 85002935156     PISSN: 02681080     EISSN: 14602237     Source Type: Journal    
DOI: 10.1093/heapol/czw062     Document Type: Review

References (194)

1. Abdoulaye I, Chastanier H, Azondekon A, Dansou A, Bruneton C. 2006. Evaluation of public awareness campaigns on counterfeit medicines in Cotonou, Benin. Med Trop (Mars) 66: 615-8.
2. Abdul-Aziz MH, Lipman J, Mouton JW, Hope WW, Roberts JA. 2015. Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Seminars in Respiratory and Critical Care Medicine 36: 136-53.
3. Access to Medicine Index. 2015. The 2016 Access to Medicine Index Methodology. http://www.accesstomedicineindex.org/sites/2015.atmindex.org/files/2015methodology-2016accesstomedicineindex-accesstomedicinefoundation.pdf, accessed 20 February 2016.
4. Agyei-Mensah S, de-Graft Aikins A. 2010. Epidemiological Transition and the Double Burden of Disease in Accra, Ghana. Journal of Urban Health 87: 879-97.
5. Almuzaini T, Choonara I, Sammons H. 2013. Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open 3: e002923.
6. Al-Worafi YM. 2014. Pharmacy practice and its challenges in Yemen. The Australasian Medical Journal 7: 17-23.
7. Amin AA, Kokwaro GO. 2007. Antimalarial drug quality in Africa. Journal of Clinical Pharmacy and Therapeutics 32: 429-40.
8. Amin AA, Snow RW. 2005. Brands, costs and registration status of antimalarial drugs in the Kenyan retail sector. Malaria Journal 4: 36.
9. Ashley E, Dhorda M, Fairhurst RM et al. 2014. Spread of Artemisinin Resistance in Plasmodium falciparum Malaria. New England Journal of Medicine 371: 411-23.
10. Asian Community Health Action Network (ACHAN) et al. 2010. Open Letter to Dr. Margaret Chan, Director General of the World Health Organization.http://www.intal.be/files/Open-letter-Margaret-Chan.pdf, accessed 29 February 2016.
11. Atemnkeng MA, De Cock K, Plaizier-Vercammen J. 2007. Quality control of active ingredients in artemisinin-derivative antimalarials within Kenya and DR Congo. Tropical Medicine & International Health 12: 68-74.
12. Attaran A. 2015. Stopping murder by medicine: introducing the model law on medicine crime. The American Journal of Tropical Medicine and Hygiene 92: 127-32.
13. Attaran A, Barry D, Basheer S, Bate R. 2012. How to achieve international action on falsified and substandard medicines. British Medical Journal 7381: 1-6.
14. Bate R, Attaran A. 2010. A counterfeit drug treaty: great idea, wrong implementation. Lancet (London, England) 376: 1446-8.
15. Bate R, Hess K. 2010. Assessing website pharmacy drug quality Safer than you think? PLoS One 5.
16. Bate R, Coticelli P, Tren R, Attaran A. 2008. Antimalarial drug quality in the most severely malarious parts of Africa-a six country study. PloS One 3: e2132.
17. Bate R, Jensen P, Hess K, Mooney L, Milligan J. 2013. Substandard and falsified anti-tuberculosis drugs: a preliminary field analysis. The International Journal of Tuberculosis and Lung Disease 17: 308-11.
18. Bate R, Jin GZ, Mathur A. 2011. Does price reveal poor-quality drugs? Evidence from 17 countries. Journal of Health Economics 30: 1150-63.
19. Bate R, Jin GZ, Mathur A. 2015. Counterfeit or Substandard? Assessing Price and Non-Price Signals of Drug Quality. Journal of Economics & Management Strategy 24: 687-711.
20. Bate R, Mooney L, Hess K. 2010a. Medicine registration and medicine quality: a preliminary analysis of key cities in emerging markets. Research and Reports in Tropical Medicine 1: 89-93.
21. Bate R, Mooney L, Hess K. 2012. Anti-infective medicine quality: analysis of basic product quality by approval status and country of manufacture. Research and Reports in Tropical Medicine 3: 57-61.
22. Bate R, Putze E, Naoshy S,McPherson A, Mooney L. 2010b. Drug Registration-a necessary but not sufficient condition for good quality drugs-a preliminary analysis of 12 countries. http://www.fightingmalaria. org/files/document/1/70/57362998355070ed9865bb.pdf, accessed 7 February 2016.
23. Bate R, Tren R, Hess K, Mooney L, Porter K. 2009a. Pilot study comparing technologies to test for substandard drugs in field settings. African Journal of Pharmacy and Pharmacology 3: 165-70.
24. Bate R, Tren R, Mooney L et al. 2009b. Pilot study of essential drug quality in two major cities in India. PloS One 4.
25. Bharati K, Ganguly NK. 2013. Tackling the malaria problem in the South-East Asia Region: need for a change in policy? The Indian Journal of Medical Research 137: 36-47.
26. Binagwaho A, Bate R, GasanaMet al. 2013. Combatting substandard and falsified medicines: a view from Rwanda. PLoS Medicine 10: e1001476.
27. Buckley GJ, Gostin LO (eds). 2013. Countering the Problem of Falsified and Substandard Drugs. The National Academies Press.
28. Caudron J-M, Ford N, Henkens M, et al. 2008. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Tropical Medicine & International Health 13: 1062-72.
29. Chalker J, Ratanawijitrasin S, Chuc NTK, Petzold M, Tomson G. 2005. Effectiveness of a multi-component intervention on dispensing practices at private pharmacies in Vietnam and Thailand-a randomized controlled trial. Social Science & Medicine 60: 131-41.
30. Chambliss WG, Carroll W. a, Kennedy D et al. 2012. Role of the pharmacist in preventing distribution of counterfeit medications. Journal of American Pharmaceutical Association 52: 195-9.
31. Chauvé M. 2008. La lutte contre la contrefaçon de médicaments en Afrique: expériences et rô le des pharmaciens. Comptes Rendus-Biologies 331: 982-5.
32. Cheng MM. 2009. Is the Drugstore Safe? Counterfeit Diabetes Products on the Shelves. Journal of Diabetes Science and Technology 3: 1516-20.
33. Chika A, Bello SO, Jimoh AO, Umar MT. 2011. The Menace of Fake Drugs: Consequences, Causes and Possible Solutions. Research Journal of Medical Sciences 5: 257-61.
34. Chuma J, Abuya T, Memusi D et al. 2009. Reviewing the literature on access to prompt and effective malaria treatment in Kenya: implications for meeting the Abuja targets. Malaria Journal 8: 243.
35. Cockburn R, Newton PN, Agyarko EK, Akunyili D, White NJ. 2005. The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Medicine 2: e100.
36. Cohen JC, Mrazek M, Hawkins L. 2007. Tackling corruption in the pharmaceutical systems worldwide with courage and conviction. Clinical Pharmacology and Therapeutics 81: 445-9.
37. Cohn J, von Schoen-Angerer T, Jambert E, Arreghini G, Childs M. 2013. When falsified medicines enter the supply chain: Description of an incident in Kenya and lessons learned for rapid response. Journal of Public Health Policy 34: 22-30.
38. Conférence Internationale des Ordres de Pharmaciens Francophones (CIOPF). 2006. Les pharmaciens s'engagent pour préserver la sécurité des patients face aux médicaments. http://www.ciopf.org/var/ciopf/storage/fckeditor/File/pharmaciens-s-engagent-pour-preserver-la-securite-des-patients-faceaux-medicaments.pdf, accessed 28 March 2016.
39. Cui L, Yan G, Sattabongkot J et al. 2012. Challenges and prospects for malaria elimination in the Greater Mekong Subregion. Acta Tropica 121: 240-5.
40. Cuomo RE, Mackey TK. 2014. An exploration of counterfeit medicine surveillance strategies guided by geospatial analysis: lessons learned from counterfeit Avastin detection in the US drug supply chain. BMJ Open 4: e006657.
41. DeCola PR. 2010. We need to 'get real' about counterfeit medicine. International Nursing Review 57: 275-6.
42. Dondorp AM, Newton PN, Mayxay M et al. 2004. Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Tropical Medicine & International Health 9: 1241-6.
43. Dondorp AM et al. 2009. Artemisinin Resistance in Plasmodium falciparum malaria. New England Journal of Medicine 455-67.
44. El-Jardali F, Akl E. a, Fadlallah R et al. 2015. Interventions to combat or prevent drug counterfeiting: a systematic review. BMJ Open 5: e006290.
45. European Commission. 2006. Summary of Community Customs Activities on Counterfeit and Piracy: Results at the European border. http://ec.europa.eu/taxation-customs/resources/documents/customs/customs-controls/counterfeit-piracy/statistics/counterf-comm-2006-en.pdf. accessed 28 March 2016.
46. European Commission. 2009. The Anti-Counterfeiting Trade Agreement (ACTA) Fact sheet. http://trade.ec.europa.eu/doclib/docs/2009/january/tradoc-142039.pdf, accessed 29 February 2016.
47. European Parliament. 2012. European Parliament rejects ACTA. http://www.europarl.europa.eu/news/en/news-room/20120703IPR48247/European-Parliament-rejects-ACTA, accessed 15 March 2016.
48. Fight The Fakes. 2016. http://fightthefakes.org/, accessed 12 January 2016.
49. Finitsis DJ, Pellowski JA, Johnson BT. 2014. Text message intervention designs to promote adherence to antiretroviral therapy (ART): a meta-analysis of randomized controlled trials. PloS One 9: e88166.
50. Free C, Phillips G, Galli L et al. 2013. The effectiveness of mobile-health technology-based health behaviour change or disease management interventions for health care consumers: a systematic review. PLoS Med 10: e1001362.
51. Galactionova K, Tediosi F, de Savigny D, Smith T, Tanner M. 2015. Effective coverage and systems effectiveness for malaria case management in sub-Saharan African countries. PloS One 10: e0127818.
52. Garuba HA, Kohler JC, Huisman AM. 2009. Globalization and Health Transparency in Nigeria ' s public pharmaceutical sector perceptions from policy makers. 13: 1-13.
53. General Pharmaceutical Council. 2016. Internet pharmacy. https://www.pharmacyregulation.org/registration/internet-pharmacy, accessed 20 February 2016.
54. Global Pharma Health Fund. 2016. GPHF Minilab Fact Sheet. http://www.gphf.org/en/minilab/factsheet.htm, accessed 4 May 2016.
55. Gomes M, Wayling S, Pang L. 1998. Interventions to improve the use of antimalarials in south-east Asia: an overview. Bulletin of the World Health Organization 76: 9-19.
56. Goodman C, Kachur SP, Abdulla S, Bloland P, Mills A. 2007. Drug shop regulation and malaria treatment in Tanzania-Why do shops break the rules, and does it matter? Health Policy and Planning 22: 393-403.
57. Government of Rwanda Ministry of Health. 2012. Third Health Sector Strategic Plan. http://www.internationalhealthpartnership.net/fileadmin/uploads/ihp/Documents/Country-pages/Rwanda/Rwanda-Health-Plan-2012-2018.pdf, accessed 29 February 2016.
58. Green MD, Hostetler DM, Nettey H, et al. 2015. Integration of novel lowcost colorimetric, laser photometric, and visual fluorescent techniques for rapid identification of falsified medicines in resource-poor areas: application to artemether-lumefantrine. The American Journal of Tropical Medicine and Hygiene 92: 8-16.
59. Harper J, Strote G. 2011. Afghanistan pharmaceutical sector development: Problems and prospects. Southern Med Review 4: 29-39.
60. Hasan SS, Ahmed SI. 2012. Medicine disaster in Pakistan points to enhanced safety role for pharmacists. The Pharmaceutical Journal. http://www.pharmaceutical-journal.com/opinion/comment/medicine-disaster-in-pakistanpoints-to-enhanced-safety-role-for-pharmacists/11096691. article. accessed 19 May 2016.
61. Heyman ML, Williams RL. 2011. Ensuring global access to quality medicines: role of the US Pharmacopeia. Journal of Pharmaceutical Sciences 100: 1280-7.
62. Ho NT, Desai D, Zaman MH. 2015. Rapid and specific drug quality testing assay for artemisinin and its derivatives using a luminescent reaction and novel microfluidic technology. The American Journal of Tropical Medicine and Hygiene 92: 24-30.
63. International Pharmaceutical Federation (FIP). 2003. Statement of policy on counterfeit medicines. http://www.fip.org/www/uploads/database-file.php?id164 & table-id, accessed 20 February 2016.
64. Ioset J-R, Kaur H. 2009. Simple field assays to check quality of current artemisinin-based antimalarial combination formulations. PloS One 4: e7270.
65. Isah AO, Pal SN, Olsson S, Dodoo A, Bencheikh RS. 2012. Specific features of medicines safety and pharmacovigilance in Africa. Therapeutic Advances in Drug Safety 3: 25-34.
66. Juhlin K, Karimi G, Ander M et al. 2015. Using VigiBase to identify substandard medicines: detection capacity and key prerequisites. Drug Safety 38: 373-82.
67. Kafu LM. 2014. Counterfeiting drugs and logistic cycle of drug supply in Libyan market. International Journal of Pharma & Bio Sciences 5: 978-82.
68. Karunamoorthi K. 2014. The counterfeit anti-malarial is a crime against humanity: A systematic review of the scientific evidence. Malaria Journal 13
69. Kaur H, Goodman C, Thompson E et al. 2008. A nationwide survey of the quality of antimalarials in retail outlets in Tanzania. PloS One 3: e3403.
70. Kaur H, Green MD, Hostetler DM, Newton PN. 2010. Antimalarial drug quality: methods to detect suspect drugs. Therapy 7: 49-57.
71. Khan AN, Khar RK. 2015. Current Scenario of Spurious and Substandard Medicines in India: A Systematic Review. Indian Journal of Pharmaceutical Sciences 77: 2-7.
72. Khan MH, Akazawa M, Dararath E et al. 2011a. Perceptions and practices of pharmaceutical wholesalers surrounding counterfeit medicines in a developing country: a baseline survey. BMC Health Services Research 11: 306.
73. Khan MH, Hatanaka K, Sovannarith T et al. 2013. Effects of packaging and storage conditions on the quality of amoxicillin-clavulanic acid-an analysis of Cambodian samples. BMC Pharmacology & Toxicology 14: 33.
74. Khan MH, Okumura J, Sovannarith T et al. 2011b. Counterfeit Medicines in Cambodia-Possible Causes. Pharmaceutical Research 28: 484-9.
75. Khan MH, Okumura J, Sovannarith T, et al. 2010. Prevalence of counterfeit anthelminthic medicines: a cross-sectional survey in Cambodia. Tropical Medicine & International Health: TM & IH 15: 639-44.
76. Khan MH, Tanimoto T, Nakanishi Y, et al. 2012. Public health concerns for anti-obesity medicines imported for personal use through the internet: a cross-sectional study. BMJ Open 2: 1-8.
77. Koesdjojo MT, Wu Y, Boonloed A, Dunfield EM, Remcho VT. 2014. Lowcost, high-speed identification of counterfeit antimalarial drugs on paper. Talanta 130: 122-7.
78. Kohler JC, Pavignani E, Michael M, et al. 2012. An examination of pharmaceutical systems in severely disrupted countries. BMC International Health and Human Rights 12: 34.
79. Kovacs S, Hawes SE, Maley SN, et al. 2014. Technologies for detecting falsified and substandard drugs in low and middle-income countries. PloS One 9: e90601.
80. Lalani M, Kaur H, Mohammed N et al. 2015. Substandard antimalarials available in afghanistan: a case for assessing the quality of drugs in resource poor settings. The American Journal of Tropical Medicine and Hygiene 92: 51-8.
81. Leslie T, Kaur H, Mohammed N et al. 2009. Epidemic of Plasmodium falciparum malaria involving substandard antimalarial drugs, Pakistan, 2003. Emerging Infectious Diseases 15: 1753-9.
82. Liang BA. 2006. Fade to black: importation and counterfeit drugs. American Journal of Law & Medicine 32: 279-323.
83. Lindquist M. 2008. VigiBase, the WHO Global ICSR Database System: Basic Facts. Drug Information Journal 42: 409-19.
84. Ling LA. 2006. How to Catch a Pirate 101: A Guide for the Investigation of Bad Wholesaling Practices. Journal of Pharmacy Practice 19: 221-6.
85. Liu X, Lewis JJ, Zhang H et al. 2015. Effectiveness of Electronic Reminders to Improve Medication Adherence in Tuberculosis Patients: A Cluster-Randomised Trial. PLOS Medicine 12: e1001876.
86. Lon CT, Tsuyuoka R, Phanouvong S et al. 2006. Counterfeit and substandard antimalarial drugs in Cambodia. Transactions of the Royal Society of Tropical Medicine and Hygiene 100: 1019-24.
87. Mackey TIMK, Liang BA. 2011. The Global Counterfeit Drug Trade: Patient Safety and Public Health Risks. Journal of Pharmaceutical Sciences 100: 4571-9.
88. Mackey TK, Liang BA. 2012. Separating online piracy from counterfeit medicines: The need for policy reform and a call to action. Health Policy and Technology 1: 120-2.
89. Mackey TK, Liang BA. 2013. Improving global health governance to combat counterfeit medicines: a proposal for a UNODC-WHO-Interpol trilateral mechanism. BMC Medicine 11: 233.
90. Mackey TK, Aung P, Liang BA. 2015a. Illicit Internet availability of drugs subject to recall and patient safety consequences. International Journal of Clinical Pharmacy 37: 1076-85.
91. Mackey TK, Cuomo R, Guerra C, Liang BA. 2015b. After counterfeit AvastinVR-what have we learned and what can be done? Nature Reviews. Clinical Oncology 12: 302-8.
92. Mackey TK, Liang BA, York P, Kubic T. 2015c. Counterfeit drug penetration into global legitimate medicine supply chains: a global assessment. The American Journal of Tropical Medicine and Hygiene 92: 59-67.
93. MalariaGEN Plasmodium falciparum Community Project 2016. Genomic epidemiology of artemisinin resistant malaria. eLife 5: 1-29.
94. mFarm. 2016. https://mfarm.co.ke/, accessed 4 May 2016.
95. Miotto O, Almagro-Garcia J, Manske M et al. 2013. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nature Genetics 45: 648-55.
96. Mita T, Tanabe K, Kita K. 2009. Spread and evolution of Plasmodium falciparum drug resistance. Parasitology International 58: 201-9.
97. Moher D, Liberati A, Tetzlaff J, Altman DG, The Prisma Group (2009). 2009. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. British Medical Journal 339.
98. mPedigree GoldKeys. 2016. http://goldkeys.org/, accessed on 4 May 2016.
99. mPedigree Network. 2016. mPedigree, http://mpedigree.net/, accessed 4 May 2016.
100. MSF Access Campaign. 2012. A BLANK CHEQUE FOR ABUSE The Anti-Counterfeiting Trade Agreement (ACTA) and its Impact on Access to Medicines. http://www.msfaccess.org/sites/default/files/MSF-assets/Access/Docs/Access-Briefing-ACTABlankCheque-ENG-2012.pdf, accessed 28 March 2016.
101. Nair A, Strauch S, Lauwo J, Ahnke RWOJ, Dressman J. 2011. Are Counterfeit or Substandard Anti-Infective Products the Cause of Treatment Failure in Papua New Guinea? Journal of Pharmaceutical Sciences 100: 5059-68.
102. National Agency for Food and Drug Administration and Control. 2014. NAFDAC enforcement of mobile authentication service (MAS). http://www.nafdac.gov.ng/index.php/regulation/draft-regulations/item/244-nafdac-enforcement-of-mobile-authentication-servicemas, accessed 15 January 2016.
103. Nayyar G, Breman J, Newton P, H J. 2012. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infectious Diseases 12: 488-96.
104. Nayyar GML, Breman JG, Herrington JE. 2015. The global pandemic of falsified medicines: laboratory and field innovations and policy perspectives. The American Journal of Tropical Medicine and Hygiene 92: 2-7.
105. Nditunze L, Makuza S, Amoroso CL et al. 2015. Assessment of Essential Medicines Stock-Outs at Health Centers in Burera District in Northern Rwanda. Rwanda Journal Series F: Medicine and Health Sciences 2: 2013-6.
106. Newton P, White N, Rozendaal J, Green M. 2002. Murder by fake drugs. British Medical Journal 324: 800-1.
107. Newton PN, Amin AA, Bird C et al. 2011a. The primacy of public health considerations in defining poor quality medicines. PLoS Medicine 8: e1001139.
108. Newton PN, Dondorp A, Green M, Mayxay M, White NJ. 2003. Counterfeit artesunate antimalarials in southeast Asia. Lancet (London, England) 362: 169.
109. Newton PN, Fernandez FM, Plançon A et al. 2008. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Medicine 5: e32.
110. Newton PN, Green MD, Fernandez FM. 2010. Impact of poor-quality medicines in the 'developing' world. Trends in Pharmacological Sciences 31: 99-101.
111. Newton PN, Green MD, Fernandez FM, Day NPJ, White NJ. 2006a. Counterfeit anti-infective drugs. The Lancet Infectious Diseases 6: 602-13.
112. Newton PN, Green MD, Mildenhall DC et al. 2011b. Poor quality vital antimalarials in Africa-an urgent neglected public health priority. Malaria Journal 10: 352.
113. Newton PN, Lee SJ, Goodman C et al. 2009. Guidelines for field surveys of the quality of medicines: A proposal. PLoS Medicine 6: 0252-7.
114. Newton PN, McGready R, Fernandez F et al. 2006b. Manslaughter by fake artesunate in Asia-will Africa be next? PLoS Medicine 3: e197.
115. Newton PN, Schellenberg D, Ashley EA et al. 2015. Quality assurance of drugs used in clinical trials: proposal for adapting guidelines. BMJ (Clinical Research Ed.) 350: h602.
116. Newton PN, Tabernero P, Dwivedi P et al. 2014. Falsified medicines in Africa: all talk, no action. The Lancet. Global Health 2: e509-10.
117. Nwokike J, Joshi MP. 2009. Assessment of Pharmacovigilance and Medicine Safety System in Rwanda. http://apps.who.int/medicinedocs/documents/s18428en/s18428en.pdf, accessed 28 March 2016.
118. Office of the United States Trade Representative. 2011. Anti-Counterfeiting Trade Agreement (ACTA). https://ustr.gov/acta, accessed 29 February 2016.
119. Oladepo O, Brieger W, Adeoye B, Lawal B, Peters D. 2011. Awareness of antimalarial policy and malaria treatment practices of patent medicine vendors in three Nigerian states. African Journal of Medical Science 40: 345-52.
120. Onwujekwe O, Kaur H, Dike N et al. 2009. Quality of anti-malarial drugs provided by public and private healthcare providers in south-east Nigeria. Malaria Journal 8: 22.
121. Pal SN, Olsson S, Brown EG. 2015. The monitoring medicines project: a multinational pharmacovigilance and public health project. Drug Safety 38: 319-28.
122. Pesic A. 2011. GSK introduces SMS service to combat Nigerian counterfeits. http://pharmexcil.org/uploadfile/ufiles/1500880404-GSK-introduces-SMS-service-to-combat-Nigerian-counterfeits%20.pdf, accessed 9 January 2016.
123. Pew Research Center. 2015. Cell Phones in Africa: Communication Lifeline. http://www.pewglobal.org/files/2015/04/Pew-Research-Center-Africa-Cell-Phone-Report-FINAL-April-15-2015.pdf, accessed 29 February 2016.
124. PharmaSecure. 2015. 'PharmaSecure advances to phase two of The Grand Challenges in TB Control program in India, sponsored by The Gates Foundation and USAID'. http://www.pharmasecure.com/pharmasecure-advances-to-phase-two-of-the-grand-challenges-in-tb-control.
125. Pisani E. 2015. Antimicrobial resistance: What does medicine quality have to do with it?. http://amr-review.org/sites/default/files/ElizabethPisaniMedicinesQualitypaper.pdf, accessed 29 February 2016.
126. Prazuck T, Falconi I, Morineau G, et al. 2002. Quality control of antibiotics before the implementation of an STD program in Northern Myanmar. Sex Transm Dis 29: 624-7.
127. President Barack Hussein Obama. 2014. President Barack Obama State of the Union Address 2014. https://www.whitehouse.gov/the-press-office/2014/01/28/president-barack-obamas-state-union-address, accessed 12 July 2015.
128. PREVENT. 2016. PREVENT initiative, at http://preventfaking.com/, accessed 4 May 2016.
129. Professor Dame Sally Davis. 2013. UK government press release: 'Antimicrobial resistance poses catastrophic threat, says Chief Medical Officer'. https://www.gov.uk/government/news/antimicrobial-resistanceposes-catastrophic-threat-says-chief-medical-officer-2, accessed 12 July 2015.
130. PROTECT. Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium. Available at http://www.imi-protect.eu/, accessed 29 February 2016.
131. Rago L, Sillo H, 't Hoen E, Zweygarth M. 2014. Regulatory framework for access to safe, effective quality medicines. Antiviral Therapy 19
132. Ranieri N, Tabernero P, Green MD et al. 2014. Evaluation of a new handheld instrument for the detection of counterfeit artesunate by visual fluorescence comparison. The American Journal of Tropical Medicine and Hygiene 91: 920-4.
133. Reason J. 2000. Human error: models and management. British Medical Journal 320: 768-70.
134. Renschler JP, Walters KM, Newton PN, Laxminarayan R. 2015. Estimated under-five deaths associated with poor-quality antimalarials in sub-saharan Africa. The American Journal of Tropical Medicine and Hygiene 92: 119-26.
135. Republic of Rwanda. 2014. Rwanda Annual Health Statistics Booklet 2014. http://moh.gov.rw/fileadmin/templates/HMIS-Docs/MOH-Statistical-Booklet-2014.pdf, accessed 29 February 2016.
136. Republic of Rwanda Ministry of Health. 2011. Guidelines for pharmacovigilance and medicine information system in Rwanda. http://spssms.msh.org/products/Rwanda-Pharmacovigilance%20Guidelines%20last%20draft%20version%2014%20June%202011.pdf, accessed 29 February 2016.
137. Risha PG, Msuya Z, Clark M, et al. 2008. The use of Minilabs to improve the testing capacity of regulatory authorities in resource limited settings: Tanzanian experience. Health Policy 87: 217-22.
138. ROA Holdings. 2015. Asian Mobile Market Forecast 2012-2015. ROA Holdings, INC. Report No.012201.
139. SafeMedicines.org. 2016. The Partnership for SafeMedicines. Available at www.safemedicines.org, accessed 20 February 2016.
140. Sengaloundeth S, Green MD, Fernandez FM et al. 2009. A stratified random survey of the proportion of poor quality oral artesunate sold at medicine outlets in the Lao PDR-Implications for therapeutic failure and drug resistance. Malaria Journal 8.
141. Shrivastava SRB, Shrivastava PS, Ramasamy J. 2014. Public health measures to fight counterfeit medicine market. International Journal of Preventive Medicine 5: 370-1.
142. Sproxil. 2016a. Personal correspondence with Sproxil via 'Contact Us' on their website: http://www.sproxil.com/contact-us.html, accessed 11 January 2016.
143. Sproxil. 2016b. Sproxil website. http://www.sproxil.com/home.html, accessed 9 January 2016.
144. Sproxil. 2016c. Over 4,600 Kenyan farmers use mobile phones to avoid counterfeit products; Agri-business client now has direct connection to farmers across the country. http://www.sproxil.com/brochure-request.html, accessed 15 January 2016.
145. Stanford Encyclopaedia of Philosophy. Stanford Encyclopaedia of Philosophy, page on 'Retributive Justice '. http://plato.stanford.edu/entries/justice-retributive/, accessed online on 12 July 2015.
146. Stenson B, Syhakhang L, Lundborg C, Eriksson B, Tomson G. 2001. Private pharmacy practice and regulation. A randomized trial in Lao P.D.R. Int J Technol Assess Health Care 17: 579-89.
147. Stephens WE, Calder A, Newton J. 2005. Source and health implications of high toxic metal concentrations in illicit tobacco products. Environmental Science and Technology 39: 479-88.
148. Supply Chain Management System (SCMS). 2013. Rwanda NSCA and Pharmaceutical Supply Chain Strategic Plan Technical Report. http://pdf.usaid.gov/pdf-docs/PA00JTCV.pdf, accessed 29 February 2016.
149. Syhakhang L, Freudenthal S, Tomson G, Wahlström R. 2004a. Knowledge and perceptions of drug quality among drug sellers and consumers in Lao PDR. Health Policy and Planning 19: 391-401.
150. Syhakhang L, Lundborg C, Lindgren B, Tomson G. 2004b. The quality of drugs in private pharmacies in Lao PDR: a repeat study in 1997 and 1999. PharmacyWorld and Science 26: 333-8.
151. Tabernero P, Fernandez FM, Green M, Guerin PJ, Newton PN. 2014. Mind the gaps-the epidemiology of poor-quality anti-malarials in the malarious world-analysis of the WorldWide Antimalarial Resistance Network database. Malaria Journal 13: 139.
152. Takahashi N, Tsuboi H, Yoshida N, et al. 2013. Investigation Into the Antinfluenza Agent Oseltamivir Distributed via the Internet in Japan. Therapeutic Innovation and Regulatory Science 47.
153. Tawab M, Reinhardt M, Flamme D, Schubert-Zsilavecz M. 2007. Arzneimittel per Mausklick: Zweifelhafte Qualitat [Medicines with a click: doubtful quality]. Pharmazeutische Zeitung 24-27.
154. Taylor D. 2014. RFID in the pharmaceutical industry: addressing counterfeits with technology. Journal of Medical Systems 38: 141.
155. The Pharmaceutical Journal News Team. 2011. Trader of fake inhalers jailed. http://www.pharmaceutical-journal.com/news-and-analysis/news/traderof-fake-inhalers-jailed/11079877.article, accessed 7 January 2016.
156. Phillips T 2007. Knockoff: The Deadly Trade in Counterfeit Goods. The True Story of the World's Fastest Growing Crimewave.
157. Tremblay M. 2013. Medicines counterfeiting is a complex problem: a review of key challenges across the supply chain. Current Drug Safety 8: 43-55.
158. U.S. Pharmacopeial Convention. Promoting the Quality of Medicines in Developing Countries (PQM). http://www.usp.org/global-health-programs/promoting-quality-medicines-pqmusaid, accessed 10 July 2015.
159. United States Food and Drug Administration. 2013. FDA Facts: FDA's Counterfeit Detection Device CD-3. http://www.fda.gov/downloads/NewsEvents/Newsroom/FactSheets/UCM349286.pdf, accessed 29 Febraury 2016.
160. US Food and Drug Administration. US Food and Drug Administration information page on ICSRs. http://www.fda.gov/ForIndustry/DataStandards/IndividualCaseSafetyReports/default.htm, accessed 5 July 2015.
161. Le Vaillant Y, Brenier C, Grange Yet al. 2012. Simultaneous Determination of Artesunate and Amodiaquine in Fixed-Dose Combination by a RP-HPLC Method with Double UV Detection: Implementation in Interlaboratory Study Involving Seven African National Quality Control Laboratories. Chromatographia 75: 617-28.
162. Veronin M. 2011. Packaging and labeling of pharmaceutical products obtained from the internet. Journal of Medical Internet Research 13: e22.
163. Veronin MA, Nguyen NT. 2008. Comparison of simvastatin tablets from the US and international markets obtained via the internet. Annals of Pharmacotherapy 42: 613-20.
164. Veronin MA, Lee E, Lewis EN. 2007. 'Insight' into drug quality: Comparison of simvastatin tablets from the US and Canada obtained via the internet. Annals of Pharmacotherapy 41: 1111-5.
165. Veronin MA, Nutan MT, Dodla UKR. 2014. Quantification of active pharmaceutical ingredient and impurities in sildenafil citrate obtained from the Internet. Therapeutic Advances in Drug Safety 5: 180-9.
166. Visser BJ, Meerveld-Gerrits J, Kroon D et al. 2015. Assessing the quality of anti-malarial drugs from Gabonese pharmacies using the MiniLabVR : a field study. Malaria Journal 14: 273.
167. Wang T, Hoag SW, Eng ML, Polli J, Pandit NS. 2015. Quality of antiretroviral and opportunistic infection medications dispensed from developing countries and Internet pharmacies. Journal of Clinical Pharmacy and Therapeutics 40: 68-75.
168. Weaver AA, Lieberman M. 2015. Paper Test Cards for Presumptive Testing of Very Low Quality Antimalarial Medications. American Journal of Tropical Medicine and Hygiene 92: 17-23.
169. Weaver AA, Reiser H, Barstis T et al. 2013. Paper analytical devices for fast field screening of beta lactam antibiotics and antituberculosis pharmaceuticals. Analytical Chemistry 85: 6453-60.
170. Wertheimer AI, Chaney NM, Santella T (2003) Counterfeit pharmaceuticals: current status and future projections. Journal of the American Pharmacists Association 43: 710-7
171. Wijesinghe P, Jayakody R, De A Seneviratne R. 2007. An assessment of the compliance with good pharmacy practice in an urban and rural district in Sri Lanka. Pharmacoepidemiol Drug Safety 16: 197-206.
172. Wilbur K. 2013. Pharmacovigilance in the Middle East: a survey of 13 arabicspeaking countries. Drug Safety 36: 25-30.
173. World Health Organization. 2003. The quality of antimalarials a study in selected african countries. http://apps.who.int/medicinedocs/en/d/Js4901e/, accessed 10 July 2015.
174. World Health Organization. 2007. Anti-malarial medicines in Kenya: availability, quality, and registration status. http://apps.who.int/medicinedocs/documents/s16424e/s16424e.pdf, accessed 7 January 2016.
175. World Health Organization. 2008. IMPACT Brochure. http://apps.who.int/impact/FinalBrochureWHA2008a.pdf?ua1, accessed 29 February 2016.
176. World Health Organization. 2009. Survey of the quality of selected antimalarial medicines circulating in Madagascar, Senegal, and Uganda. http://apps.who.int/medicinedocs/en/d/Js17069e/, accessed 10 July 2015.
177. World Health Organization 2010a. Growing threat from counterfeit medicines. Bulletin of theWorld Health Organization 88: 247-8.
178. World Health Organization. 2010b. 63rd World Health Assembly, A63/INF.DOC./3, 'Counterfeit medical products'. Page 3, paragraph 12. http://apps.who.int/gb/ebwha/pdf-files/WHA63/A63-ID3-en.pdf, accessed 28 March 2016.
179. World Health Organization. 2012. 65th World Health Assembly A65/23. Report of the Working Group of Member States on Substandard/Spurious/Falsely-Labelled/Falsified/Counterfeit Medical Products. http://apps.who.int/gb/ebwha/pdf-files/WHA65/A65-23-en.pdf, accessed 28 March 2016.
180. World Health Organization. 2014. WHO Director-General addresses ministerial conference on antimicrobial resistance, http://www.who.int/dg/speeches/2014/amr-conference/en/, accessed 12 July 2015.
181. World Health Organization. 2015a. First African Medicines Regulatory Authorities Conference-Final Report. Addis Ababa, Ethiopia, 31 October-3 November 2005, http://apps.who.int/medicinedocs/documents/s17809en/s17809en.pdf, accessed 5 July 2015.
182. World Health Organization. 2015b. Report of the fourth meeting of the Member State mechanism on substandard/spurious/falsely-labelled/falsified/counterfeit medical products
183. World Health Organization. 2015c. WHO List of Prequalified Quality Control Laboratories. http://apps.who.int/prequal/, accessed 15 January 2016.
184. World Health Organization. 2016a. Definitions of SSFFC Medical Products, http://www.who.int/medicines/regulation/ssffc/definitions/en/, accessed 29 February 2016.
185. World Health Organization. 2016b. Pharmacovigilance information page, http://www.who.int/medicines/areas/quality- safety/safety-efficacy/pharmvigi/en/, accessed 3 May 2016.
186. World Health Organization. 2016c. Medical product alert. http://www.who.int/medicines/publications/drugalerts/en/, accessed 29 Februray 2016.
187. World Health Organization. 2016d. WHO VigiBase Programme Members, http://who-umc.org/ DynPage.aspx?id 100653 & mn17347 & mn27252 & mn37322 & mn47442, accessed 3 May 2016.
188. World Health Organization. 2016e. Joining the WHO programme for International Drug Monitoring. World Health Organisation, Geneva, Switzerland. www.who-umc.org on, accessed 5 January 2016.
189. World Health Organization. 2016f. International Medical Products Anti-Counterfeiting Taskforce-IMPACT. http://apps.who.int/impact/en/, accessed 29 February 2016.
190. World Health Organization. 2016g. WHO Checklist. Be Aware: Tool for visual inspection of medicines. A checklist for visual inspection of medicines in order to identify suspicious products for further examination. http://www.whpa.org/Toolkit-BeAware-Inspection.pdf, accessed 28 March 2016.
191. World Wide Antimalarial Resistance Network (WWARN). 2016. Antimalarial Quality (AQ) Surveyor. http://www.wwarn.org/about-us/drug-quality/ wwarn-antimalarial-quality-surveyor, accessed 20 February 2016.
192. Yeung S, Lawford HLS, Tabernero P et al. 2015. Quality of Antimalarials at the Epicenter of Antimalarial Drug Resistance: Results from an Overt and Mystery Client Survey in Cambodia. The American Journal of Tropical Medicine and Hygiene 92: 39-50.
193. Yoshida N, Khan MH, Tabata H et al. 2014. A cross-sectional investigation of the quality of selected medicines in Cambodia in 2010. BMC Pharmacology & Toxicology 15: 13.
194. Zurovac D, Ochola SA, Midia B, Snow RW. 2005. The quality of sulfadoxine-pyrimethamine prescriptions, counselling and drug-dispensing practices, for children in Kenya. Annals of Tropical Medicine & Parasitology 99: 321-4.